Бюрократы, Администраторы, Редакторы
3741
правка
Mikhail Blagosklonny: различия между версиями
Перейти к навигации
Перейти к поиску
нет описания правки
Rodion (обсуждение | вклад) (Новая страница: «{{Languages|Михаил Благосклонный}}») |
Rodion (обсуждение | вклад) Нет описания правки |
||
| Строка 1: | Строка 1: | ||
{{Languages|Михаил Благосклонный}} | {{Languages|Михаил Благосклонный}} | ||
{{Infobox scientist | |||
| name = Mikhail Blagosklonny | |||
| image = | |||
| image_size = | |||
| caption = | |||
| birth_date = | |||
| birth_place = | |||
| field = [[Anti-aging medicine]], [[oncology]] | |||
| work_institutions = {{plainlist|1= | |||
*[[New York Medical College]] | |||
*[[Roswell Park Comprehensive Cancer Center]] | |||
}} | |||
| alma_mater = [[First Pavlov State Medical University of St. Peterburg]] | |||
| education = | |||
| website = | |||
}} | |||
'''Mikhail Blagosklonny''' was a scientist who studied [[cancer]] and [[aging]]. He died in October 2024. He was an adjunct faculty member at [[Roswell Park Comprehensive Cancer Center]] in [[Buffalo, New York]].<ref name=":0">{{Cite web|title=About Mikhail Blagosklonny|url=https://www.roswellpark.org/mikhail-blagosklonny|access-date=May 14, 2021|website=[[Roswell Park Comprehensive Cancer Center]]}}</ref> | |||
==Career== | |||
Blagosklonny earned both his [[M.D.]] in internal medicine and his [[PhD]] in experimental medicine and cardiology from the [[First Pavlov State Medical University of St. Petersburg]].{{citation needed|date=November 2017}} He was appointed associate professor of medicine at [[New York Medical College]], Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute ([[Albany, New York]]). Blagosklonny held this position until 2009, when he was appointed professor of oncology at [[Roswell Park Comprehensive Cancer Center]].<ref name="Roswell Park Cancer Institute">{{citation | |||
| date = May 2009 | |||
| doi = 10.4161/cbt.8.9.8899 | |||
| issue = 9 | |||
| journal = Cancer Biology & Therapy | |||
| pages = 753–752 | |||
| title = Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute | |||
| volume = 8| doi-access = free | |||
}}</ref> | |||
Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging ([[biogerontology]]) and anti-aging drugs.<ref>{{Cite journal|date=May 2009|title=Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute|journal=Cancer Biology & Therapy|volume=8|issue=9|pages=753–752|doi=10.4161/cbt.8.9.8899|doi-access=free}}</ref> Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.<ref name=":0" /> | |||
==Rapamycin and aging== | |||
Blagosklonny has formulated a hypothesis about the possible role of [[TOR signaling]] in aging and cancer and proposed using [[rapamycin]], a popular cancer drug as a possible treatment for life extension.<ref>{{cite journal |first=David|last=Stipp|title=A New Path to Longevity |journal=[[Scientific American]] |date=2011 |volume=306|issue=1|doi=10.1038/scientificamerican0112-32 |pages=32–39|pmid=22279832|bibcode=2011SciAm.306f..32S}}</ref> He advocates for rapamycin use in longevity research.<ref>{{cite news |url=https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-|title = Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015|newspaper = Bloomberg.com|date = 12 February 2015|accessdate = November 20, 2016}}</ref> | |||
== Editorial activities== | |||
Blagosklonny is [[editor-in-chief]] of [[Aging (journal)|''Aging'']],<ref>{{Cite web |url=http://www.impactaging.com/editors.html |archive-url=https://web.archive.org/web/20090125145825/http://impactaging.com/editors.html |url-status=dead |archive-date=2009-01-25 |work=Aging |title=Editorial Board |accessdate=2016-11-20}}</ref> [[Cell Cycle (journal)|''Cell Cycle'']],<ref>{{Cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20 |work=Cell Cycle |title=Editorial Board |accessdate=2016-11-20 |publisher=[[Taylor & Francis]]}}</ref> and ''[[Oncotarget]]''.<ref>{{Cite web |url=http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board |work=Oncotarget |title=Editorial Board |accessdate=2016-11-20}}</ref> In addition, he is associate editor of ''[[Cancer Biology & Therapy]]''<ref>{{cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20 |work=Cancer Biology & Therapy |title=Editorial board |publisher=Taylor & Francis|accessdate=2016-11-20}}</ref> and a member of the [[editorial board]] of ''[[Cell Death & Differentiation]]''.<ref>{{cite web |url=http://www.nature.com/cdd/about.html |work=[[Cell Death & Differentiation]] |title=About the journal |accessdate=2016-11-20}}</ref> | |||
The [[peer review]] process employed by ''Oncotarget'' has been criticized by [[Jeffrey Beall]],<ref name=Beall>{{cite web|last1=Beall |first1=Jeffrey |authorlink1=Jeffrey Beall |title=Oncotarget's Peer Review is Highly Questionable |url=https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ |website=Scholarly Open Access |accessdate=2016-11-20 |date=19 April 2016 |url-status=dead |archiveurl=https://web.archive.org/web/20160420235706/https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ |archivedate=20 April 2016 }}</ref> a university librarian and expert on [[predatory open access publishing]], who also included ''Oncotarget'' and ''Aging'' on his list of "potential, possible, or probable predatory scholarly open-access journals"<ref>{{cite web|last1=Beall |first1=Jeffrey |authorlink1=Jeffrey Beall |title=LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals |url=https://scholarlyoa.com/individual-journals/ |website=Scholarly Open Access |accessdate=19 April 2016 |date=2016-11-20 |url-status=dead |archiveurl=https://web.archive.org/web/20161202192038/https://scholarlyoa.com/individual-journals/ |archivedate=2 December 2016 }}</ref> in July 2015.<ref name=Beall/> Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his [[Author-level metrics|personal citation impact]].<ref>{{cite web|url=https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ |title=Mikhail Blagosklonny's Journal Aging: A Review |website=Scholarly Open Access |date=6 December 2016 |accessdate=17 January 2017 |archiveurl=https://web.archive.org/web/20161224004259/https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ |archivedate=24 December 2016 |url-status=dead }}</ref> | |||
==Health== | |||
Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.<ref>{{cite web |url=https://www.mikhailblagosklonny.com/blog/my-battle-with-cancer/|title = My battle with cancer|date = 26 October 2023}}</ref> He died in October 2024 at the age of 63.<ref>{{cite web|url=https://www.rapamycin.news/t/passing-of-dr-misha-blagoskonny/16658|title=Passing of Dr. Misha Blagoskonny|work=Rapamycin News|access-date=2024-10-09}}</ref> | |||
==References== | |||
{{reflist|30em}} | |||
* {{Wikipedia|Mikhail Blagosklonny}} | |||